ANN ARBOR, Mich. - ENDRA Life Sciences Inc. (NASDAQ: NASDAQ:NDRA), specializing in Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, recently announced the issuance of three new patents across major global markets. These patents are aimed at enhancing the capabilities of the TAEUS system used in medical procedures such as surgical monitoring and thermal ablation.
The U.S. patent, numbered 11844650, describes a sleeve-type probe that improves the absorption of radiofrequency energy, leading to stronger thermoacoustic signals and reduced noise. This innovation is expected to provide clearer measurements for clinical use.
In China, patent ZL2021800757024 covers a system that measures temperature within the human body, particularly during thermal ablation treatments. The technology ensures that healthy tissues are preserved while effectively targeting cancerous cells.
The European patent, EP3902490, details a method for monitoring tissue temperature during various surgical procedures, potentially improving outcomes for patients undergoing treatments like thermotherapy and cryotherapy.
With these additions, ENDRA's intellectual property portfolio now comprises 74 issued patents worldwide. The company's Chief Technology Officer, Michael Thornton, emphasized the importance of these patents in supporting ENDRA's commitment to advancing thermoacoustic technology and addressing clinical needs.
ENDRA Life Sciences is recognized for pioneering TAEUS®, a technology designed to work alongside existing ultrasound systems to provide MRI-like tissue characterization at a fraction of the cost. The company initially targets the assessment and monitoring of Steatotic Liver Disease, which affects over two billion people globally.
This expansion of ENDRA's patent estate underscores the company's dedication to securing its technological advancements and maintaining a competitive edge in the market. The information for this article is based on a press release statement from ENDRA Life Sciences Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.